readthroughSign in
Oct 2, 2026Weekly roundupUpdated

Boehringer Ingelheim registers five new trials, spanning oncology, obesity, and ILD screening

New registrations cover a Phase Ia BI 3968621 cancer study, two Phase IIIb survodutide trials, a vicadrostat/empagliflozin bioequivalence study, and a Boehringer-backed ILD screening initiative.

Boehringer Ingelheim registered five new studies, none yet recruiting.

  • BI 3968621, a novel agent, enters a Phase Ia dose escalation trial, alone or combined with ezabenlimab, in adults with advanced solid tumors. The study is a first-in-human, multicentre Phase Ia dose escalation trial investigating safety, tolerability, pharmacokinetics, and preliminary antitumour activity.1 It plans to enroll 90 participants, estimated, with a start date of 2026-10-26.1
  • Survodutide, also known as BI 456906, is being tested in peri- and post-menopausal women with overweight or obesity in the Phase IIIb "SYNCHRONIZE-HERA" trial. The trial evaluates efficacy and safety of survodutide in peri- and post-menopausal women with overweight or obesity over 52 weeks.2 Enrollment is estimated at 600 participants, with an estimated start of 2026-10-31.2
  • Survodutide is also entering the Phase IIIb "ELEVATE-LIVER" trial, examining effects on cardiac structure and function in people with overweight or obesity and MASLD. The study targets adults with metabolic dysfunction-associated steatotic liver disease, assessing how survodutide affects heart structure and function.3 Enrollment is estimated at 600 participants, with an estimated start of 2026-10-23.3
  • A Phase 1 bioequivalence trial will compare two tablet formulations of vicadrostat combined with empagliflozin in healthy volunteers. The main objective is to establish the bioequivalence of two different formulations of vicadrostat / empagliflozin in healthy male and female trial participants following oral administration.4 Enrollment is estimated at 36 participants, with an estimated start of 2026-10-14.4
  • Boehringer Ingelheim is listed as a collaborator on a quality-improvement study testing EHR-embedded tools to boost interstitial lung disease screening in patients with rheumatoid arthritis or systemic sclerosis, sponsored by the Foundation for Advancing Science Technology Education and Research. The initiative tests whether EHR-built tools, including patient symptom surveys and clinician alerts, can increase ILD screening rates.5 The study expects to include about 800 patients.5

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.